Medpace Holdings, Inc. (NASDAQ:MEDP) Shares Sold by Ameritas Investment Partners Inc.

Ameritas Investment Partners Inc. trimmed its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 2.7% during the second quarter, Holdings Channel reports. The institutional investor owned 5,008 shares of the company’s stock after selling 141 shares during the quarter. Ameritas Investment Partners Inc.’s holdings in Medpace were worth $2,063,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in MEDP. Thrivent Financial for Lutherans increased its position in shares of Medpace by 44.2% in the 2nd quarter. Thrivent Financial for Lutherans now owns 8,946 shares of the company’s stock valued at $3,685,000 after purchasing an additional 2,741 shares during the last quarter. Pacer Advisors Inc. grew its stake in shares of Medpace by 182.4% during the second quarter. Pacer Advisors Inc. now owns 13,968 shares of the company’s stock worth $5,753,000 after purchasing an additional 9,022 shares in the last quarter. Skandinaviska Enskilda Banken AB publ increased its holdings in Medpace by 56.2% in the second quarter. Skandinaviska Enskilda Banken AB publ now owns 139,849 shares of the company’s stock valued at $57,611,000 after buying an additional 50,302 shares during the last quarter. Davidson Capital Management Inc. raised its stake in Medpace by 4.6% in the second quarter. Davidson Capital Management Inc. now owns 7,764 shares of the company’s stock valued at $3,198,000 after buying an additional 340 shares in the last quarter. Finally, Joseph Group Capital Management lifted its holdings in Medpace by 12.2% during the 2nd quarter. Joseph Group Capital Management now owns 2,525 shares of the company’s stock worth $1,040,000 after buying an additional 275 shares during the last quarter. Institutional investors and hedge funds own 77.98% of the company’s stock.

Medpace Stock Performance

NASDAQ MEDP opened at $365.70 on Friday. The firm’s fifty day moving average is $378.15 and its two-hundred day moving average is $391.95. Medpace Holdings, Inc. has a one year low of $227.21 and a one year high of $459.77. The firm has a market cap of $11.33 billion, a PE ratio of 37.28, a P/E/G ratio of 1.74 and a beta of 1.35.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings data on Monday, July 22nd. The company reported $2.75 EPS for the quarter, beating the consensus estimate of $2.54 by $0.21. Medpace had a return on equity of 55.14% and a net margin of 16.74%. The firm had revenue of $528.10 million during the quarter, compared to the consensus estimate of $528.41 million. During the same period in the prior year, the business earned $1.93 EPS. The firm’s revenue was up 14.6% compared to the same quarter last year. Research analysts predict that Medpace Holdings, Inc. will post 11.66 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on MEDP shares. Truist Financial assumed coverage on Medpace in a report on Thursday, August 1st. They issued a “hold” rating and a $415.00 price objective on the stock. Robert W. Baird reduced their price objective on shares of Medpace from $430.00 to $413.00 and set an “outperform” rating for the company in a research report on Friday. TD Cowen dropped their target price on shares of Medpace from $452.00 to $434.00 and set a “buy” rating on the stock in a research report on Wednesday, July 24th. Mizuho started coverage on shares of Medpace in a research report on Tuesday, May 28th. They issued a “buy” rating and a $435.00 price target for the company. Finally, William Blair reaffirmed an “outperform” rating on shares of Medpace in a report on Wednesday, September 11th. Three equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $420.88.

Medpace Profile

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.